Full Press Release Details
AC Immune Announces Late Breaker Presentation By Genentech at Ctad on Phase 2 Lauriet Study of Semorinemab in Mild to Moderate Alzheimer s Disease.
ACIU
AC Immune Announces Late Breaker Presentation By Genentech at Ctad on Phase 2 Lauriet Study of Semorinemab in Mild to Moderate Alzheimer s Disease
Key Takeaway: AC Immune Announces Late Breaker Presentation By Genentech at Ctad on Phase 2 Lauriet Study of Semorinemab in Mild to Moderate Alzheimer s Disease